Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease

Table 1 Demographic characteristics of patients enrolled in the study. Updated Sydney scores are given

Parameters	Pretreatment	Posttreatment	Chronicgastritis
N of patients	56		16
Age (mean ± SD)	60.13 ± 17.38		57.11 ± 15.81
Male/Female	46/10		8/8
Non smoking/smoking	16/40		6/10
Gastric ulcer	21	0	-
Duodenal ulcer	35	0	-
History of NSAID use	33/52		4/16
H pylori positive/negative	41/11a	7/45b	11/5
Patients with evidence of gastritis	49/52a	34/52d	13/16
(Total updated Sydney Score > 0)
Site of gastric inflammation
Antrum (no of patients)	28	21	8
Corpus (no of patients)	8	6	3
Disseminated (no of patients)	13	7	5
Total updated Sydney score (mean ± SD)	4.69 ± 1.93a	2.69 ± 1.22f	4.27 ± 0.65
Neutrophil infiltration score (mean ± SD)	1.77 ± 0.59a	0.81 ± 0.32f	1.73 ± 0.73
Monocyte infiltration score (mean ± SD)	2.15 ± 0.68a	1.05 ± 0.61f	1.73 ± 0.38
Lymphocyte infiltration score (mean ± SD)	0.87 ± 0.35a	0.13 ± 0.08c	0.69 ± 0.32
Mucosal atrophy score (mean ± SD)	0.55 ± 0.17a	0.38 ± 0.11e	0.58 ± 0.30
Intestinal metaplasia (mean ± SD)	0.29 ± 0.04a	0.13 ± 0.08e	0.19 ± 0.07
Density of H pylori (mean ± SD)	1.56 ± 0.28a	0.33 ± 0.07f	1.45 ± 0.39

^aP vs chronic gastritis, non significant; ^b,d,fP < 0.01,

^cP < 0.05, vs pre-treatment scores.

^eP vs pre-treatment scores; non significant.